pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›mRESVIA
drug · vaccine component
save

respiratory syncytial virus vaccine

Phase 2updated 6mo ago
by $MRNA Moderna, Inc.🔗 ChEMBL
Phase 2
community read0 votes

Vaccine component drug with a maximum clinical stage of Approval, with an approval for respiratory syncytial virus infection.

targets

Fusion glycoprotein F0

all catalysts(0)

nothing on the calendar yet

Trials studying respiratory syncytial virus vaccine

  • phase3Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)recruitingn=25,000
  • phase2Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Aboveactive not recruitingn=522
  • phase2Safety and Efficacy of BARS13 in the Elderlycompletedn=125

News(5)

  • Moderna enjoys stable vaccine sales thanks to global COVID uptake
    While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.
    biospace · 8d ago
  • Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
    Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
    biopharma_dive · 15d ago
  • GSK vaccine sales miss expectations amid falling demand from adults
    With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.
    biospace · 17d ago
  • GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum
    The layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.
    biospace · 1mo ago
  • GSK lays off 650 staffers amid closure of German vaccine manufacturing site
    GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.
    biospace · 2mo ago
brand
mRESVIA
trade names
Mresvia
MOA
Fusion glycoprotein F0 vaccine antigen
indication
Respiratory Syncytial Virus (RSV) Infections
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?